Data from Dana-Farber Cancer Institute Provide New Insights into Adverse Drug Reactions (Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial)

Media coverage

• Title	Data from Dana-Farber Cancer Institute Provide New Insights into Adverse Drug Reactions (Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial)
  Media name/outlet	Clinical Trials Daily
  Country/Territory	United States
  Date	19/10/23
  Persons	Joseph Sparano